Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DM002 |
| Synonyms | |
| Therapy Description |
DM002 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting ERBB3 (HER3) and MUC1 linked to monomethyl auristatin E (MMAE), which may inhibit the growth of ERBB3 (HER3) and MUC1-expressing tumors (Cancer Res (2024) 84 (6_Supplement): 2621, Cancer Res (2023) 83 (8_Supplement): LB214). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DM002 | DM 002|DM-002 | HER3 (ERBB3) Antibody 28 MUC1 Antibody 8 | DM002 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting ERBB3 (HER3) and MUC1 linked to monomethyl auristatin E (MMAE), which may inhibit the growth of ERBB3 (HER3) and MUC1-expressing tumors (Cancer Res (2024) 84 (6_Supplement): 2621, Cancer Res (2023) 83 (8_Supplement): LB214). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06751329 | Phase I | DM002 | A Study of DM002 in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |